Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Intelligent and effective informatic deconvolution of "Big Data" and its future impact on the quantitative nature of neurodegenerative disease therapy.

Maudsley S, Devanarayan V, Martin B, Geerts H; Brain Health Modeling Initiative (BHMI).

Alzheimers Dement. 2018 Jul;14(7):961-975. doi: 10.1016/j.jalz.2018.01.014. Epub 2018 Mar 15. Review.

PMID:
29551332
2.

Feedback from the European Bioanalysis Forum: focus workshop on current analysis of immunogenicity: best practices and regulatory hurdles.

Goodman J, Cowen S, Devanarayan V, Egging D, Emrich T, Golob M, Kramer D, McNally J, Munday J, Nelson R, Pedras-Vasconcelos JA, Piironen T, Sickert D, Skibeli V, Fjording MS, Timmerman P.

Bioanalysis. 2018 Feb;10(4):197-204. doi: 10.4155/bio-2017-4971. Epub 2018 Jan 18.

3.

Minimum Significant Ratio – A Statistic to Assess Assay Variability.

Haas JV, Eastwood BJ, Iversen PW, Devanarayan V, Weidner JR.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2013 Nov 1 [updated 2017 Nov 20].

4.

Assay Operations for SAR Support.

Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, Farmen MW, Iturria SJ, Iversen PW, Kahl SD, Moore RA, Sawyer BD, Weidner J.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2017 Nov 20].

5.

A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression.

Llano DA, Bundela S, Mudar RA, Devanarayan V; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

PLoS One. 2017 Aug 3;12(8):e0182098. doi: 10.1371/journal.pone.0182098. eCollection 2017.

6.

Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points.

Devanarayan V, Smith WC, Brunelle RL, Seger ME, Krug K, Bowsher RR.

AAPS J. 2017 Sep;19(5):1487-1498. doi: 10.1208/s12248-017-0107-3. Epub 2017 Jul 21.

PMID:
28733862
7.

Patient subgroup identification for clinical drug development.

Huang X, Sun Y, Trow P, Chatterjee S, Chakravartty A, Tian L, Devanarayan V.

Stat Med. 2017 Apr 30;36(9):1414-1428. doi: 10.1002/sim.7236. Epub 2017 Feb 1.

PMID:
28147447
8.

Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge.

Geerts H, Dacks PA, Devanarayan V, Haas M, Khachaturian ZS, Gordon MF, Maudsley S, Romero K, Stephenson D; Brain Health Modeling Initiative (BHMI).

Alzheimers Dement. 2016 Sep;12(9):1014-1021. doi: 10.1016/j.jalz.2016.04.008. Epub 2016 May 26. Review.

9.

2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3--LBA, biomarkers and immunogenicity).

Amaravadi L, Song A, Myler H, Thway T, Kirshner S, Devanarayan V, Ni YG, Garofolo F, Birnboeck H, Richards S, Gupta S, Luo L, Kingsley C, Salazar-Fontana L, Fraser S, Gorovits B, Allinson J, Barger T, Chilewski S, Fjording MS, Haidar S, Islam R, Jaitner B, Kamerud J, Katori N, Krinos-Fiorotti C, Lanham D, Ma M, McNally J, Morimoto A, Mytych D, Nogueira da Costa A, Papadimitriou A, Pillutla R, Ray S, Safavi A, Savoie N, Schaefer M, Shih J, Smeraglia J, Skelly MF, Spond J, Staack RF, Stouffer B, Tampal N, Torri A, Welink J, Yang TY, Zoghbi J.

Bioanalysis. 2015 Dec;7(24):3107-24. doi: 10.4155/bio.15.226. Epub 2015 Dec 4.

10.

Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib.

McKeegan EM, Ansell PJ, Davis G, Chan S, Chandran RK, Gawel SH, Dowell BL, Bhathena A, Chakravartty A, McKee MD, Ricker JL, Carlson DM, Ramalingam SS, Devanarayan V.

Lung Cancer. 2015 Nov;90(2):296-301. doi: 10.1016/j.lungcan.2015.09.011. Epub 2015 Sep 15.

PMID:
26424209
11.

Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.

Jani D, Allinson J, Berisha F, Cowan KJ, Devanarayan V, Gleason C, Jeromin A, Keller S, Khan MU, Nowatzke B, Rhyne P, Stephen L.

AAPS J. 2016 Jan;18(1):1-14. doi: 10.1208/s12248-015-9820-y. Epub 2015 Sep 16. Review.

12.

Evaluation of miR-122 as a Serum Biomarker for Hepatotoxicity in Investigative Rat Toxicology Studies.

Sharapova T, Devanarayan V, LeRoy B, Liguori MJ, Blomme E, Buck W, Maher J.

Vet Pathol. 2016 Jan;53(1):211-21. doi: 10.1177/0300985815591076. Epub 2015 Jun 29.

PMID:
26123229
13.

Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

Zhang W, Yu Y, Hertwig F, Thierry-Mieg J, Zhang W, Thierry-Mieg D, Wang J, Furlanello C, Devanarayan V, Cheng J, Deng Y, Hero B, Hong H, Jia M, Li L, Lin SM, Nikolsky Y, Oberthuer A, Qing T, Su Z, Volland R, Wang C, Wang MD, Ai J, Albanese D, Asgharzadeh S, Avigad S, Bao W, Bessarabova M, Brilliant MH, Brors B, Chierici M, Chu TM, Zhang J, Grundy RG, He MM, Hebbring S, Kaufman HL, Lababidi S, Lancashire LJ, Li Y, Lu XX, Luo H, Ma X, Ning B, Noguera R, Peifer M, Phan JH, Roels F, Rosswog C, Shao S, Shen J, Theissen J, Tonini GP, Vandesompele J, Wu PY, Xiao W, Xu J, Xu W, Xuan J, Yang Y, Ye Z, Dong Z, Zhang KK, Yin Y, Zhao C, Zheng Y, Wolfinger RD, Shi T, Malkas LH, Berthold F, Wang J, Tong W, Shi L, Peng Z, Fischer M.

Genome Biol. 2015 Jun 25;16:133. doi: 10.1186/s13059-015-0694-1.

14.

Workshop Report: AAPS Workshop on Method Development, Validation, and Troubleshooting of Ligand-Binding Assays in the Regulated Environment.

Kelley M, Stevenson L, Golob M, Devanarayan V, Pedras-Vasconcelos J, Staack RF, Jenkins R, Booth B, Wakshull E, Bowsher R, Rock M, Dudal S, DeSilva B.

AAPS J. 2015 Jul;17(4):1019-24. doi: 10.1208/s12248-015-9767-z. Epub 2015 Apr 30.

15.

The quintessence of immunogenicity reporting for biotherapeutics.

Shankar G, Arkin S, Devanarayan V, Kromminga A, Quarmby V, Richards S, Subramanyam M, Swanson S.

Nat Biotechnol. 2015 Apr;33(4):334-6. doi: 10.1038/nbt.3181. No abstract available.

PMID:
25850051
16.

Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development.

Khan MU, Bowsher RR, Cameron M, Devanarayan V, Keller S, King L, Lee J, Morimoto A, Rhyne P, Stephen L, Wu Y, Wyant T, Lachno DR.

Bioanalysis. 2015;7(2):229-42. doi: 10.4155/bio.14.274.

17.

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer.

Ramalingam SS, Shtivelband M, Soo RA, Barrios CH, Makhson A, Segalla JG, Pittman KB, Kolman P, Pereira JR, Srkalovic G, Belani CP, Axelrod R, Owonikoko TK, Qin Q, Qian J, McKeegan EM, Devanarayan V, McKee MD, Ricker JL, Carlson DM, Gorbunova VA.

J Clin Oncol. 2015 Feb 10;33(5):433-41. doi: 10.1200/JCO.2014.55.7173. Epub 2015 Jan 5.

18.

Immunoassay Methods.

Cox KL, Devanarayan V, Kriauciunas A, Manetta J, Montrose C, Sittampalam S.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2014 Dec 24].

19.

A PRIM approach to predictive-signature development for patient stratification.

Chen G, Zhong H, Belousov A, Devanarayan V.

Stat Med. 2015 Jan 30;34(2):317-42. doi: 10.1002/sim.6343. Epub 2014 Oct 27.

20.

The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance.

Wang C, Gong B, Bushel PR, Thierry-Mieg J, Thierry-Mieg D, Xu J, Fang H, Hong H, Shen J, Su Z, Meehan J, Li X, Yang L, Li H, Łabaj PP, Kreil DP, Megherbi D, Gaj S, Caiment F, van Delft J, Kleinjans J, Scherer A, Devanarayan V, Wang J, Yang Y, Qian HR, Lancashire LJ, Bessarabova M, Nikolsky Y, Furlanello C, Chierici M, Albanese D, Jurman G, Riccadonna S, Filosi M, Visintainer R, Zhang KK, Li J, Hsieh JH, Svoboda DL, Fuscoe JC, Deng Y, Shi L, Paules RS, Auerbach SS, Tong W.

Nat Biotechnol. 2014 Sep;32(9):926-32. doi: 10.1038/nbt.3001. Epub 2014 Aug 24.

21.

Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations.

Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, Quarmby V, Richards S, Schneider CK, Subramanyam M, Swanson S, Verthelyi D, Yim S; American Association of Pharmaceutical Scientists.

AAPS J. 2014 Jul;16(4):658-73. doi: 10.1208/s12248-014-9599-2. Epub 2014 Apr 24.

22.

Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease.

Llano DA, Devanarayan V, Simon AJ; Alzheimer’s Disease Neuroimaging Initiative (ADNI).

Alzheimer Dis Assoc Disord. 2013 Jul-Sep;27(3):233-43. doi: 10.1097/WAD.0b013e31826d597a.

PMID:
23023094
23.

HTS Assay Validation.

Iversen PW, Beck B, Chen YF, Dere W, Devanarayan V, Eastwood BJ, Farmen MW, Iturria SJ, Montrose C, Moore RA, Weidner JR, Sittampalam GS.

In: Sittampalam GS, Coussens NP, Brimacombe K, Grossman A, Arkin M, Auld D, Austin C, Baell J, Bejcek B, Caaveiro JMM, Chung TDY, Dahlin JL, Devanaryan V, Foley TL, Glicksman M, Hall MD, Haas JV, Inglese J, Iversen PW, Kahl SD, Kales SC, Lal-Nag M, Li Z, McGee J, McManus O, Riss T, Trask OJ Jr., Weidner JR, Wildey MJ, Xia M, Xu X, editors. Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004-.
2012 May 1 [updated 2012 Oct 1].

24.

Minimum significant ratio of selectivity ratios (MSRSR) and confidence in ratio of selectivity ratios (CRSR): quantitative measures for selectivity ratios obtained by screening assays.

Goedken ER, Devanarayan V, Harris CM, Dowding LA, Jakway JP, Voss JW, Wishart N, Jordan DC, Talanian RV.

J Biomol Screen. 2012 Aug;17(7):857-67. doi: 10.1177/1087057112447108. Epub 2012 May 14.

PMID:
22584786
25.

A hidden Markov model-based algorithm for identifying tumour subtype using array CGH data.

Zhang K, Yang Y, Devanarayan V, Xie L, Deng Y, Donald S.

BMC Genomics. 2011 Dec 23;12 Suppl 5:S10. doi: 10.1186/1471-2164-12-S5-S10. Epub 2011 Dec 23.

26.

Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease.

Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A.

Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):31-42. doi: 10.1159/000323417. Epub 2011 Jan 14.

27.

Cerebrospinal fluid cytokine dynamics differ between Alzheimer disease patients and elderly controls.

Llano DA, Li J, Waring JF, Ellis T, Devanarayan V, Witte DG, Lenz RA.

Alzheimer Dis Assoc Disord. 2012 Oct-Dec;26(4):322-8. doi: 10.1097/WAD.0b013e31823b2728.

PMID:
22089638
28.

Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics.

Gupta S, Devanarayan V, Finco D, Gunn GR 3rd, Kirshner S, Richards S, Rup B, Song A, Subramanyam M.

J Pharm Biomed Anal. 2011 Jul 15;55(5):878-88. doi: 10.1016/j.jpba.2011.03.038. Epub 2011 Apr 6. Review.

PMID:
21531522
29.

Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.

Llano DA, Laforet G, Devanarayan V; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimer Dis Assoc Disord. 2011 Jan-Mar;25(1):73-84. doi: 10.1097/WAD.0b013e3181f5b8d8.

PMID:
20847637
30.

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.

Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD Jr, Oberthuer A, Thomas RS, Paules RS, Fielden M, Barlogie B, Chen W, Du P, Fischer M, Furlanello C, Gallas BD, Ge X, Megherbi DB, Symmans WF, Wang MD, Zhang J, Bitter H, Brors B, Bushel PR, Bylesjo M, Chen M, Cheng J, Cheng J, Chou J, Davison TS, Delorenzi M, Deng Y, Devanarayan V, Dix DJ, Dopazo J, Dorff KC, Elloumi F, Fan J, Fan S, Fan X, Fang H, Gonzaludo N, Hess KR, Hong H, Huan J, Irizarry RA, Judson R, Juraeva D, Lababidi S, Lambert CG, Li L, Li Y, Li Z, Lin SM, Liu G, Lobenhofer EK, Luo J, Luo W, McCall MN, Nikolsky Y, Pennello GA, Perkins RG, Philip R, Popovici V, Price ND, Qian F, Scherer A, Shi T, Shi W, Sung J, Thierry-Mieg D, Thierry-Mieg J, Thodima V, Trygg J, Vishnuvajjala L, Wang SJ, Wu J, Wu Y, Xie Q, Yousef WA, Zhang L, Zhang X, Zhong S, Zhou Y, Zhu S, Arasappan D, Bao W, Lucas AB, Berthold F, Brennan RJ, Buness A, Catalano JG, Chang C, Chen R, Cheng Y, Cui J, Czika W, Demichelis F, Deng X, Dosymbekov D, Eils R, Feng Y, Fostel J, Fulmer-Smentek S, Fuscoe JC, Gatto L, Ge W, Goldstein DR, Guo L, Halbert DN, Han J, Harris SC, Hatzis C, Herman D, Huang J, Jensen RV, Jiang R, Johnson CD, Jurman G, Kahlert Y, Khuder SA, Kohl M, Li J, Li L, Li M, Li QZ, Li S, Li Z, Liu J, Liu Y, Liu Z, Meng L, Madera M, Martinez-Murillo F, Medina I, Meehan J, Miclaus K, Moffitt RA, Montaner D, Mukherjee P, Mulligan GJ, Neville P, Nikolskaya T, Ning B, Page GP, Parker J, Parry RM, Peng X, Peterson RL, Phan JH, Quanz B, Ren Y, Riccadonna S, Roter AH, Samuelson FW, Schumacher MM, Shambaugh JD, Shi Q, Shippy R, Si S, Smalter A, Sotiriou C, Soukup M, Staedtler F, Steiner G, Stokes TH, Sun Q, Tan PY, Tang R, Tezak Z, Thorn B, Tsyganova M, Turpaz Y, Vega SC, Visintainer R, von Frese J, Wang C, Wang E, Wang J, Wang W, Westermann F, Willey JC, Woods M, Wu S, Xiao N, Xu J, Xu L, Yang L, Zeng X, Zhang J, Zhang L, Zhang M, Zhao C, Puri RK, Scherf U, Tong W, Wolfinger RD; MAQC Consortium.

Nat Biotechnol. 2010 Aug;28(8):827-38. doi: 10.1038/nbt.1665. Epub 2010 Jul 30.

31.

Identification of distinct plasma biomarker signatures in patients with rapid and slow declining forms of COPD.

Devanarayan V, Scholand MB, Hoidal J, Leppert MF, Crackower MA, O'Neill GP, Gervais FG.

COPD. 2010 Feb;7(1):51-8. doi: 10.3109/15412550903499530.

PMID:
20214463
32.

Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.

Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H, Elmore SW, Kroeger PE, Tse C, Rosenberg SH, Anderson MG.

Mol Cancer Ther. 2010 Mar;9(3):545-57. doi: 10.1158/1535-7163.MCT-09-0651. Epub 2010 Feb 23.

33.

Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products.

Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirschner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E.

J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81. doi: 10.1016/j.jpba.2008.09.020. Epub 2008 Sep 19. Review.

PMID:
18993008
34.

First demonstration of cerebrospinal fluid and plasma A beta lowering with oral administration of a beta-site amyloid precursor protein-cleaving enzyme 1 inhibitor in nonhuman primates.

Sankaranarayanan S, Holahan MA, Colussi D, Crouthamel MC, Devanarayan V, Ellis J, Espeseth A, Gates AT, Graham SL, Gregro AR, Hazuda D, Hochman JH, Holloway K, Jin L, Kahana J, Lai MT, Lineberger J, McGaughey G, Moore KP, Nantermet P, Pietrak B, Price EA, Rajapakse H, Stauffer S, Steinbeiser MA, Seabrook G, Selnick HG, Shi XP, Stanton MG, Swestock J, Tugusheva K, Tyler KX, Vacca JP, Wong J, Wu G, Xu M, Cook JJ, Simon AJ.

J Pharmacol Exp Ther. 2009 Jan;328(1):131-40. doi: 10.1124/jpet.108.143628. Epub 2008 Oct 14.

35.

Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects.

Wu G, Sankaranarayanan S, Tugusheva K, Kahana J, Seabrook G, Shi XP, King E, Devanarayan V, Cook JJ, Simon AJ.

Clin Biochem. 2008 Aug;41(12):986-96. doi: 10.1016/j.clinbiochem.2008.04.022. Epub 2008 May 6.

PMID:
18489907
36.

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products.

Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, Barrett YC, Devanarayan V, Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G, Zuckerman LA, Stebbins CC, Mire-Sluis A.

J Immunol Methods. 2008 Apr 20;333(1-2):1-9. doi: 10.1016/j.jim.2008.01.001. Epub 2008 Jan 29. Review.

PMID:
18275969
37.

Confirmatory reanalysis of incurred bioanalytical samples.

Rocci ML Jr, Devanarayan V, Haughey DB, Jardieu P.

AAPS J. 2007 Oct 5;9(3):E336-43. doi: 10.1208/aapsj0903040. Review.

38.

A prototypical process for creating evidentiary standards for biomarkers and diagnostics.

Altar CA, Amakye D, Bounos D, Bloom J, Clack G, Dean R, Devanarayan V, Fu D, Furlong S, Hinman L, Girman C, Lathia C, Lesko L, Madani S, Mayne J, Meyer J, Raunig D, Sager P, Williams SA, Wong P, Zerba K.

Clin Pharmacol Ther. 2008 Feb;83(2):368-71. Epub 2007 Dec 19.

PMID:
18091762
39.

Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.

Henry JR, Li Y, Warshawsky AM, Brozinick JT, Hawkins ED, Misener EA, Briere DA, Montrose-Rafizadeh C, Zink RW, Yumibe NP, Ajamie RT, Wilken B, Devanarayan V.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6293-7. Epub 2006 Sep 26.

PMID:
17005393
40.

Fit-for-purpose method development and validation for successful biomarker measurement.

Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, Rogers JA, Millham R, O'Brien PJ, Sailstad J, Khan M, Ray C, Wagner JA.

Pharm Res. 2006 Feb;23(2):312-28. Epub 2006 Jan 12.

PMID:
16397743
41.

Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay.

Ray CA, Dumaual C, Willey M, Fill J, O'Brien PJ, Gourley I, Devanarayan V, Konrad RJ.

J Pharm Biomed Anal. 2006 Apr 11;41(1):189-95.

PMID:
16321496
42.

Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum.

Ray CA, Bowsher RR, Smith WC, Devanarayan V, Willey MB, Brandt JT, Dean RA.

J Pharm Biomed Anal. 2005 Jan 4;36(5):1037-44.

PMID:
15620530
43.

Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products.

Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA.

J Immunol Methods. 2004 Jun;289(1-2):1-16.

PMID:
15251407
44.

Human SPF45, a splicing factor, has limited expression in normal tissues, is overexpressed in many tumors, and can confer a multidrug-resistant phenotype to cells.

Sampath J, Long PR, Shepard RL, Xia X, Devanarayan V, Sandusky GE, Perry WL 3rd, Dantzig AH, Williamson M, Rolfe M, Moore RE.

Am J Pathol. 2003 Nov;163(5):1781-90.

45.

A very early induction of major vault protein accompanied by increased drug resistance in U-937 cells.

Hu Y, Stephen AG, Cao J, Tanzer LR, Slapak CA, Harrison SD, Devanarayan V, Dantzig AH, Starling JJ, Rome LH, Moore RE.

Int J Cancer. 2002 Jan 10;97(2):149-56.

46.

Circulating ghrelin levels are decreased in human obesity.

Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML.

Diabetes. 2001 Apr;50(4):707-9.

48.

Ritonavir and saquinavir combination therapy for the treatment of HIV infection.

Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, Cohen C, Poretz D, Markowitz M, Follansbee S, Angel JB, McMahon D, Ho D, Devanarayan V, Rode R, Salgo M, Kempf DJ, Granneman R, Leonard JM, Sun E.

AIDS. 1999 Feb 4;13(2):213-24.

PMID:
10202827

Supplemental Content

Loading ...
Support Center